



## Mylan – Recall of daptomycin injection

- On July 7, 2020, [Mylan announced](#) a voluntary, user level recall of one lot of [daptomycin for injection](#) due to the presence of particulate matter in one single-dose vial.
- The recalled lot was distributed nationwide between April 2020 and May 2020:

Product Description	NDC#	Lot# (Expiration Date)
Daptomycin for Injection, 500 mg/vial, 20 mL vial	67457-813-50	7605112 (10/2021)

- Daptomycin for injection is an injectable antibacterial indicated for the treatment of complicated skin and skin structure infections and *Staphylococcus aureus* bloodstream infections (bacteremia) in adult patients.
- Intravenous administration of a solution containing visible particulates could lead to serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.
- To date, Mylan has not received any reports of adverse events related to this recall.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Contact Mylan Customer Relations by phone at **1-800-796-9526** or by email at [\*\*customer.service@mylan.com\*\*](mailto:customer.service@mylan.com) for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.